Terms ending in 2041
Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,427,541 | Salt Forms of a Complement Component C5A Receptor In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 12,734,166 | Compositions and Methods for Treating Inflammatory Bowel Disease Using CCR9 Inhibitor and ANTI-IL-23 Blocking Antibodies In force · Medium confidence | Chemocentryx, Inc. | In force | Medium confidence | |
| US 11,866,429 | Heteroaryl-Biphenyl Amines for the Treatment of PD-L1 Diseases In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,844,790 | Methods of Treating Hidradenitis Suppurativa In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,883,391 | Compositions and Methods for Treating Inflammatory Bowel Disease Using CCR9 Inhibitor and ANTI-IL-23 Blocking Antibodies In force · High confidence | Chemocentryx, Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.